clinical trial · NCT04333654
Hydroxychloroquine in Outpatient Adults With COVID-19
Coronavirus InfectionHydroxychloroquine SAR321068Placebo
brief summary
Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: * To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in outpatient adults with COVID-19 * To assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19
started
Apr 12, 2020
primary completion
May 26, 2020
completion
May 26, 2020
last updated
Sep 23, 2025
detailed description
The duration of the study per participant will be around 18 days (1 or 2 days of screening followed by a 10-day treatment period and a 4 to 6 days follow-up period)
official title
A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol